Serum anti-glycan antibody biomarkers for inflammatory bowel disease diagnosis and progression: A systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 18, Issue 10, 2012, Pages 1872-1884

  Kaul, Amit ^a   Hutfless, Susan ^a   Liu, Ling ^a   Bayless, Theodore M ^a   Marohn, Michael R ^a   Li, Xuhang ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti glycan; Crohn's disease (CD); disease complication; inflammatory bowel disease; meta analysis; serological biomarkers; surgery for IBD; systemic review; ulcerative colitis (UC)

Indexed keywords

ANTIBODY; ANTIGLYCAN ANTIBODY; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ARTICLE; CROHN DISEASE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; ENTERITIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

ANTIBODIES, ANTI-IDIOTYPIC; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; HUMANS; INFLAMMATORY BOWEL DISEASES; META-ANALYSIS AS TOPIC; POLYSACCHARIDES; PROGNOSIS;

EID: 84866393051     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22862     Document Type: Article

References (40)

1. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 1627-1640. (Pubitemid 46722636)
2. De Hertogh G, Aerssens J, Geboes KP, et al. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol. 2008; 14: 845-852. (Pubitemid 351325023)
3. Xavier RJ, Podolsky DK,. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448: 427-434. (Pubitemid 47123518)
4. Vermeire S, Rutgeerts P,. Antibody responses in Crohn's disease. Gastroenterology. 2004; 126: 601-604. (Pubitemid 38182317)
5. Targan SR, Landers CJ, Yang H, et al. Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology. 2005; 128: 2020-2028. (Pubitemid 40824710)
6. Papp M, Altorjay I, Dotan N, et al. New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort. Am J Gastroenterol. 2008; 103: 665-681. (Pubitemid 351405992)
7. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004; 99: 2376-2384. (Pubitemid 40039369)
8. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101: 360-367. (Pubitemid 43381681)
9. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007; 56: 1394-1403. (Pubitemid 47517833)
10. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut. 2004; 53: 1117-1122. (Pubitemid 38961964)
11. Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology. 1996; 110: 1810-1819. (Pubitemid 26169219)
12. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 1998; 93: 1306-1310. (Pubitemid 29076932)
13. Satsangi J, Landers CJ, Welsh KI, et al. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis. 1998; 4: 18-26. (Pubitemid 128699832)
14. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, et al. IBD serological panels: facts and perspectives. Inflamm Bowel Dis. 2007; 13: 1561-1566.
15. Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007; 13: 2028-2036. (Pubitemid 46795837)
16. Joossens S, Colombel JF, Landers C, et al. Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut. 2006; 55: 1667-1669. (Pubitemid 44629225)
17. Dotan I, Fishman S, Dgani Y, et al. Antibodies against Laminaribioside and Chitobioside are novel serologic markers in Crohn's disease. Gastroenterology. 2006; 131: 366-378. (Pubitemid 44142445)
18. Dotan N, Altstock RT, Schwarz M, et al. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus. 2006; 15: 442-450. (Pubitemid 44147091)
19. Wallace BC, Schmid CH, Lau J, et al. Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol. 2009; 9: 80.
20. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp, 2009.
21. Henckaerts L, Pierik M, Joossens M, et al. Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease. Gut. 2007; 56: 1536-1542. (Pubitemid 350033192)
22. Lakatos PL, Altorjay I, Mandi Y, et al. Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? Tissue Antigens. 2008; 71: 552-559. (Pubitemid 351697252)
23. Malickova K, Lukas M, Donoval R, et al. Novel anti-carbohydrate autoantibodies in patients with inflammatory bowel disease: are they useful for clinical practice? Clin Lab. 2006; 52: 631-638. (Pubitemid 44883591)
24. Rieder F, Schleder S, Wolf A, et al. Serum anti-glycan antibodies predict complicated Crohn's disease behavior: a cohort study. Inflamm Bowel Dis. 2010; 16: 1367-1375.
25. Rieder F, Lopez R, Franke A, et al. Characterization of changes in serum anti-glycan antibodies in Crohn's disease - a longitudinal analysis. PLoS One. 2011; 6: e18172.
26. Rieder F, Schleder S, Wolf A, et al. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior. Inflamm Bowel Dis. 2010; 16: 263-274.
27. Seow CH, Stempak JM, Xu W, et al. Novel anti-glycan antibodies related to inflammatory bowel disease diagnosis and phenotype. Am J Gastroenterol. 2009; 104: 1426-1434.
28. Koutroubakis IE, Drygiannakis D, Tsirogianni A, et al. Anti-glycan antibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2011; 56: 845-852.
29. Simondi D, Mengozzi G, Betteto S, et al. Anti-glycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 645-651. (Pubitemid 351742981)
30. Malickova K, Lakatos PL, Bortlik M, et al. Anticarbohydrate antibodies as markers of inflammatory bowel disease in a Central European cohort. Eur J Gastroenterol Hepatol. 2010; 22: 144-150.
31. Rejchrt S, Drahosova M, Kopacova M, et al. Antilaminaribioside and antichitobioside antibodies in inflammatory bowel disease. Folia Microbiol (Praha). 2008; 53: 373-376.
32. Dotan I,. Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig Dis. 2009; 27: 206-211.
33. Lakatos PL, Papp M, Rieder F,. Serologic anti-glycan antibodies in inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 406-412.
34. Lakatos PL, Altorjay I, Szamosi T, et al. Hungarian IBD StudyGroup. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis. 2009; 15: 365-374.
35. Li X, Conklin L, Alex P,. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008; 14: 5115-5124.
36. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet. 2008; 40: 955-962
37. Franke A, McGovern DP, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010; 42: 1118-1125.
38. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011; 43: 246-252.
39. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005; 19 (Suppl A): 5-36.
40. Price AB,. Overlap in the spectrum of non-specific inflammatory bowel disease-'colitis indeterminate.' J Clin Pathol. 1978; 31: 567-577. (Pubitemid 8358785)